SHANGHAI FUDAN H YC-,10 (FDY) - Total Assets
Based on the latest financial reports, SHANGHAI FUDAN H YC-,10 (FDY) holds total assets worth €2.39 Billion EUR (≈ $2.79 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore SHANGHAI FUDAN H YC-,10 debt service capacity to assess how comfortably operating cash covers total debt obligations.
SHANGHAI FUDAN H YC-,10 - Total Assets Trend (2021–2025)
This chart illustrates how SHANGHAI FUDAN H YC-,10's total assets have evolved over time, based on quarterly financial data. See what is SHANGHAI FUDAN H YC-,10's book value for net asset value and shareholders' equity analysis.
SHANGHAI FUDAN H YC-,10 - Asset Composition Analysis
Current Asset Composition (December 2025)
SHANGHAI FUDAN H YC-,10's total assets of €2.39 Billion consist of 62.1% current assets and 37.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 48.0% |
| Accounts Receivable | €201.34 Million | 8.4% |
| Inventory | €33.21 Million | 1.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €60.87 Million | 2.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SHANGHAI FUDAN H YC-,10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SHANGHAI FUDAN H YC-,10 market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SHANGHAI FUDAN H YC-,10's current assets represent 62.1% of total assets in 2025, a decrease from 69.3% in 2021.
- Cash Position: Cash and equivalents constituted 48.0% of total assets in 2025, up from 43.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 4.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 8.4% of total assets.
SHANGHAI FUDAN H YC-,10 Competitors by Total Assets
Key competitors of SHANGHAI FUDAN H YC-,10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.64 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
SHANGHAI FUDAN H YC-,10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.05 | 3.88 | 3.88 |
| Quick Ratio | 5.91 | 3.77 | 3.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.24 Billion | €1.39 Billion | €1.39 Billion |
SHANGHAI FUDAN H YC-,10 - Advanced Valuation Insights
This section examines the relationship between SHANGHAI FUDAN H YC-,10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.17 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -7.6% |
| Total Assets | €2.39 Billion |
| Market Capitalization | $103.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values SHANGHAI FUDAN H YC-,10's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: SHANGHAI FUDAN H YC-,10's assets decreased by 7.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SHANGHAI FUDAN H YC-,10 (2021–2025)
The table below shows the annual total assets of SHANGHAI FUDAN H YC-,10 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.39 Billion ≈ $2.79 Billion |
-7.57% |
| 2024-12-31 | €2.59 Billion ≈ $3.02 Billion |
-10.09% |
| 2023-12-31 | €2.88 Billion ≈ $3.36 Billion |
-3.34% |
| 2022-12-31 | €2.98 Billion ≈ $3.48 Billion |
+7.01% |
| 2021-12-31 | €2.78 Billion ≈ $3.25 Billion |
-- |
About SHANGHAI FUDAN H YC-,10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more